Discovery of Novel Anti-prion Compounds Using In Silico and In Vitro Approaches
Citations Over TimeTop 10% of 2015 papers
Abstract
Prion diseases are associated with the conformational conversion of the physiological form of cellular prion protein (PrP(C)) to the pathogenic form, PrP(Sc). Compounds that inhibit this process by blocking conversion to the PrP(Sc) could provide useful anti-prion therapies. However, no suitable drugs have been identified to date. To identify novel anti-prion compounds, we developed a combined structure- and ligand-based virtual screening system in silico. Virtual screening of a 700,000-compound database, followed by cluster analysis, identified 37 compounds with strong interactions with essential hotspot PrP residues identified in a previous study of PrP(C) interaction with a known anti-prion compound (GN8). These compounds were tested in vitro using a multimer detection system, cell-based assays, and surface plasmon resonance. Some compounds effectively reduced PrP(Sc) levels and one of these compounds also showed a high binding affinity for PrP(C). These results provide a promising starting point for the development of anti-prion compounds.
Related Papers
- → G protein-coupled receptors: In silico drug discovery in 3D(2004)146 cited
- → Prediction of Protein Essentiality Based on Genomic Data(2002)77 cited
- → In Silico Identification and Characterization of Effector Catalogs(2011)13 cited
- → In Silico Expression Analysis(2016)1 cited
- Two novel alternatively spliced transcripts of Prkar 1b gene of mouse: Identification using a novel approach of In-silico and molecular biology techniques(2011)